Profile data is unavailable for this security.
About the company
Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.
- Revenue in CNY (TTM)277.20m
- Net income in CNY-101.80m
- Incorporated2003
- Employees475.00
- LocationLionco Pharmaceutical Group Co LtdMedicine Valley Industrial ParkNo. 16 Medicine Valley Erheng RoadNational Hi-tech Industrial Dvlpmnt ZneSHANNAN 856000ChinaCHN
- Phone+86 8 937830999
- Fax+86 8 937830888
- Websitehttp://www.lingkang.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai New World Co Ltd | 1.13bn | 45.48m | 4.57bn | 1.20k | 100.57 | 1.08 | -- | 4.03 | 0.0703 | 0.0703 | 1.75 | 6.53 | 0.201 | 3.94 | 10.25 | 942,735.10 | 0.7905 | 0.5242 | 1.05 | 0.7249 | 38.77 | 33.70 | 3.93 | 2.71 | 1.57 | -- | 0.1158 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Zhejiang Shouxiangu Pharmaceuticl Co Ltd | 713.75m | 233.79m | 4.57bn | 1.14k | 19.34 | 2.05 | -- | 6.41 | 1.19 | 1.19 | 3.63 | 11.26 | 0.2367 | 0.7194 | 7.25 | 624,455.80 | 7.75 | 10.04 | 9.09 | 11.63 | 80.01 | 83.66 | 32.75 | 28.29 | 3.48 | -- | 0.2098 | 47.86 | -5.39 | 8.93 | -8.39 | 18.78 | 12.23 | 17.13 |
| Tibet Weixinkang Pharmaceutical Co Ltd | 1.26bn | 247.04m | 4.59bn | 701.00 | 18.58 | 3.10 | -- | 3.66 | 0.5677 | 0.5677 | 2.89 | 3.41 | 0.6778 | 16.41 | 5.56 | 1,791,483.00 | 13.33 | 8.20 | 17.01 | 11.13 | 53.45 | 50.20 | 19.67 | 11.53 | 3.27 | -- | 0.0075 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Yabao Pharmaceutical Group Co Ltd | 2.83bn | 220.70m | 4.64bn | 4.14k | 21.10 | 1.57 | -- | 1.64 | 0.3057 | 0.3057 | 3.86 | 4.10 | 0.7389 | 3.51 | 6.66 | 683,686.80 | 5.11 | 2.82 | 6.38 | 3.97 | 52.85 | 59.20 | 6.92 | 4.19 | 2.04 | 129.51 | 0.0313 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Chengdu Olymvax Biopharmaceuticals Inc | 530.47m | -8.70m | 4.68bn | 471.00 | -- | 5.14 | -- | 8.83 | -0.0219 | -0.0219 | 1.31 | 2.24 | 0.3301 | 0.3685 | 1.04 | 1,126,255.00 | -0.9143 | 3.17 | -1.28 | 4.68 | 94.19 | 93.00 | -2.77 | 7.44 | 1.67 | -0.5392 | 0.2915 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Pulike Biological Engineering Inc | 1.09bn | 101.68m | 4.73bn | 1.68k | 46.16 | 1.77 | -- | 4.35 | 0.296 | 0.296 | 3.13 | 7.72 | 0.3373 | 2.48 | 2.65 | 646,748.50 | 3.16 | 7.64 | 3.73 | 8.96 | 60.45 | 62.57 | 9.36 | 17.85 | 2.51 | -- | 0.0086 | 52.48 | 1.84 | 15.55 | 3.99 | 5.17 | 41.58 | 18.47 |
| ZhuZhou QianJin Pharmaceutical Co., Ltd | 3.73bn | 291.57m | 4.75bn | 5.34k | 16.18 | 1.97 | -- | 1.27 | 0.6922 | 0.6922 | 8.84 | 5.69 | 0.835 | 3.88 | 10.04 | 699,947.80 | 8.25 | 8.99 | 15.12 | 16.21 | 45.06 | 44.59 | 9.88 | 10.03 | 2.18 | -- | 0.09 | 68.27 | -5.66 | 2.68 | 5.53 | 4.64 | -1.06 | -2.64 |
| Lionco Pharmaceutical Group Co Ltd | 277.20m | -101.80m | 4.86bn | 475.00 | -- | 5.68 | -- | 17.54 | -0.144 | -0.144 | 0.3828 | 1.19 | 0.1843 | 2.48 | 4.41 | 583,571.30 | -6.77 | 0.7396 | -7.85 | 0.9562 | 41.77 | 80.88 | -36.73 | 2.08 | 4.94 | -4.74 | 0.2409 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
| Jinyao Pharmaceutical Co Ltd | 3.52bn | 152.00m | 4.90bn | 2.68k | 32.24 | 1.60 | -- | 1.39 | 0.139 | 0.139 | 3.22 | 2.79 | 0.574 | 2.43 | 9.06 | 1,313,392.00 | 3.39 | 1.91 | 5.65 | 3.40 | 41.79 | 46.33 | 5.90 | 3.31 | 0.9536 | 14.68 | 0.189 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
| Shanghai OPM Biosciences Co Ltd | 287.29m | 38.09m | 5.04bn | 285.00 | 132.20 | 2.40 | -- | 17.56 | 0.3324 | 0.3324 | 2.52 | 18.31 | 0.1259 | 2.23 | 3.59 | 1,008,039.00 | 1.63 | 4.34 | 1.69 | 4.65 | 57.28 | 58.31 | 12.93 | 23.40 | 17.02 | -- | 0.0311 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
Data as of Nov 13 2024. Currency figures normalised to Lionco Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 43.40k | 0.01% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 19.30k | 0.00% |
| SWS MU Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
